Gaize, Inc. announced that it has completed the world’s largest clinical trial investigating cannabis impairment. The 350-participant study used Gaize’s portable, and non-invasive testing device to investigate changes in eye movement and pupillary reflex action. The use of cannabis has grown rapidly in recent years as it has become legalized in more and more jurisdictions, and as cultural acceptance grows. However, there has historically not been a device capable of detecting active impairment from cannabis. Further, the precise characteristics of eye movement and the changes that occur as a result of of impairment has been inadequately researched.

The trial was conducted in partnership with dicentra, a contract research organization in Toronto, Canada. It included both measurements of participants prior to and after having consumed legally …

Full story available on Benzinga.com